Halozyme looks to US restart of ViroPharma's Cinryze study to validate rHuPH20
This article was originally published in Scrip
San Diego-based Halozyme Therapeutics president and CEO Gregory Frost minimised the impact of concerns surrounding Baxter's subcutaneous HyQ treatment for primary immunodeficiency disorder after the US FDA issued guidance that will allow ViroPharma to restart clinical trials for Cinryze (human C1 esterase inhibitor) using Halozyme's recombinant human hyaluronidase (rHuPH20).
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.